Please assess the completion status of the following clinical trial:

Trial Title: Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of neuroblastoma by 1 of the following methods:~  * Histopathology~ * Bone marrow involvement AND elevated urinary catecholamines~* High-risk disease, defined by 1 of the following:~  * Stage 4 disease with MYCN amplification (any age) or without MYCN amplification (\> 18 months of age)~ * MYCN-amplified stage 3 disease (unresectable and any age)~ * MYCN-amplified stage 4S disease~* Metastatic disease~* Tumor progression or persistent disease (at metastatic or primary site) after intensive conventional chemotherapy~* Must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive MIBG or PET scans) or measurable (CT scan or MRI) disease documented after completion of prior systemic therapy~PATIENT CHARACTERISTICS:~* Platelet count \> 25,000/mm\^3~* ANC \> 500/mm\^3~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of allergy to mouse proteins, beta-glucan, mushrooms, or yeast~* No active life-threatening infections~* No severe major organ toxicity~  * Concurrent toxicity must be ≤ grade 2 except for the following, which may be grade 3:~    * Myelosuppression~   * Hearing loss~   * Alopecia~   * Anorexia~   * Nausea~   * Hyperbilirubinemia from TPN~   * Anxiety~   * Hypomagnesemia~* No prior HAMA titer \> 1,000 U/mL by ELISA~PRIOR CONCURRENT THERAPY:~* No concurrent supplemental beta-glucan in food (e.g., bran cereals or mushrooms) or as complementary medicine~* No other concurrent systemic anticancer medications (e.g., hormonal agents, chemotherapy, investigational agents, or immunotherapy)~  * Concurrent isotretinoin allowed after the second course of study treatment is completed or if the patient develops human antimouse antibody (HAMA)

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Beta-Glucan and Monoclonal Antibody 3F8 (Type: EXPERIMENTAL): This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer \< 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete